

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Caput et al.

Serial No.: 09/125,005

Filed: July 30, 1998

Group Art Unit: 1642

Examiner: Ungar, S.

For: PURIFIED SR-p70 PROTEIN

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence to denosited on the date indicated below

Partal Service as first

Assistant Commissioner for Patents, Washington, DC 20231.

Name

RESPONSE

Date

This is responsive to the Office Action mailed April 12, 2000 in the aboveidentified application setting a one-month period for response. Pursuant to the Petition for Extension of Time Under 37 C.F.R. § 1.136(a) submitted herewith the due date for response is extended to August 12, 2000. This response is therefore timely.

Claims 1-38 are in the application. Restriction is required under 35 U.S.C. § 121 among 117 Groups variously directed to polypeptides, polynucleotides, primers/probes and methods of use thereof in therapeutic treatment and diagnosis, each of said Groups apparently representing what the Examiner consideres to be a separate and distinct invention.

Applicants hereby elect for prosecution the Examiner's Group 3, the polypeptide of SEQ ID No. 6 which is read on by claims 1-6, 25 and 33-36.

Dated: August 9, 2000

Sanofi-Synthelabo Inc. Patent Department 9 Great Valley Parkway P.O. Box 3026

Malvern, PA 19355 Tel.: (610) 889-6338 Fax: (610) 889-8799 Respectfully submitted,

PAUL E. DUPONT

Registration No. 27,438